Clinical Trials Logo

Filter by:
NCT ID: NCT04359433 Withdrawn - Clinical trials for Cardiometabolic Risk

Intermittent Exercise Among Students

Start date: August 2, 2021
Phase: N/A
Study type: Interventional

Evaluate the effectiveness of intermittency anaerobic exercise interventions among the students with high risk of cardiometabolic .

NCT ID: NCT04325932 Withdrawn - Clinical trials for Intracranial Arteriosclerosis

Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis

Start date: January 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether Urinary Kallikrein has an additional effect on enhancing collateral circulation in symptomatic intracranial atherosclerotic patients under clopidogrel and aspirin dual antiplatelet therapy.

NCT ID: NCT04298814 Withdrawn - COVID-19 Clinical Trials

Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia

Start date: August 7, 2020
Phase:
Study type: Observational

To analyze the intubation with severe covid-19 pneumonia, the infection rate of anesthesiologist after intubation, and summarizes the experience of how to avoid the infection of anesthesiologist and ensure the safety of patients with severe covid-19 pneumonia.

NCT ID: NCT04293692 Withdrawn - COVID-19 Clinical Trials

Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus

Start date: February 24, 2020
Phase: N/A
Study type: Interventional

The 2019 novel coronavirus pneumonia outbroken in Wuhan, China, which spread quickly to 26 countries worldwide and presented a serious threat to public health. It is mainly characterized by fever, dry cough, shortness of breath and breathing difficulties. Some patients may develop into rapid and deadly respiratory system injury with overwhelming inflammation in the lung. Currently, there is no effective treatment in clinical practice. The present clinical trial is to explore the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) therapy for novel coronavirus pneumonia patients.

NCT ID: NCT04287686 Withdrawn - COVID-19 Clinical Trials

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

Start date: February 2020
Phase: N/A
Study type: Interventional

This is an open label, randomized, controlled, pilot clinical study in patients with COVID-19, to obtain preliminary biologic, physiologic, and clinical data in patients with COVID-19 treated with rhACE2 or control patients, to help determine whether a subsequent Phase 2B trial is warranted.

NCT ID: NCT04280913 Withdrawn - Clinical trials for Coronavirus Disease 2019

Clinical Outcomes of Patients With COVID19

Start date: February 22, 2020
Phase:
Study type: Observational

As of February 17th, 2020, China has 70635 confirmed cases of coronavirus disease 2019 (COVID-19), including 1772 deaths. Human-to-human spread of virus via respiratory droplets is currently considered to be the main route of transmission. The number of patients increased rapidly but the impact factors of clinical outcomes among hospitalized patients are still unclear.

NCT ID: NCT04280588 Withdrawn - Clinical trials for Coronavirus Disease (COVID-19)

Fingolimod in COVID-19

Start date: February 22, 2020
Phase: Phase 2
Study type: Interventional

Although immune-inflammatory treatment is not routinely recommended to be used for SARS-CoV-2 pneumonia, according to the pathological findings of pulmonary oedema and hyaline membrane formation, timely and appropriate use of immune modulator together with ventilator support should be considered for the severe patients to prevent ARDS development. The sphingosine-1-phosphate receptor regulators Fingolimod (FTY720) is an effective immunology modulator which has been widely used in multiple sclerosis.The aim of this study was to determine whether the efficacy of fingolimod for a novel coronavirus disease (COVID-19).

NCT ID: NCT04272710 Withdrawn - 2019-nCoV Clinical Trials

Prognositc Factors in COVID-19 Patients Complicated With Hypertension

Start date: January 25, 2020
Phase:
Study type: Observational

There are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China.

NCT ID: NCT04270461 Withdrawn - Clinical trials for Hepatocellular Carcinoma

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Start date: March 17, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.

NCT ID: NCT04251767 Withdrawn - Clinical trials for COVID-19 Complicated With Refractory Intestinal Infections

Washed Microbiota Transplantation for Patients With 2019-nCoV Infection

Start date: February 5, 2020
Phase: N/A
Study type: Interventional

Gut dysbiosis co-exists in patients with coronavirus pneumonia. Some of these patients would develop secondary bacterial infections and antibiotic-associated diarrhea (AAD). The recent study on using washed microbiota transplantation (WMT) as rescue therapy in critically ill patients with AAD demonstrated the important clinical benefits and safety of WMT. This clinical trial aims to evaluate the outcome of WMT combining with standard therapy for patients with 2019-novel coronavirus pneumonia, especially for those patients with dysbiosis-related conditions.